Suomeksi

Pinealon: dosage in studies

Updated 15 Oct 2026 Author: About 2 min read Drafted with the help of AI; sources and claims checked separately.

Not a recommendation, not treatment guidance. This page shows only what published human studies used, with sources. This site does not say how much anyone should use of any substance. The content and quality of a product bought online or as a supplement are not controlled like a medicine's.

Information on pinealon doses in humans comes from only one small Russian study, in which railway locomotive crew workers took pinealon capsules for two weeks [1]B.

In three other Russian human studies pinealon was given alone or with vesugen, but no dose is given in the English abstracts of the publications [2, 3, 4]B.

Doses used in studies

Doses used in published human studies. Not a recommendation.
StudyParticipantsDoseFrequencyDurationSource and level
Nazimko et al. 2012 Railway locomotive crew workers; number of participants and comparison group not given 100 µg in a capsule Twice a day 2 weeks [1]B

Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed

Units: µg = microgram, written mcg in the calculator. A milligram (mg) is a thousand times larger.

Notes

The study measured biological age and adaptation scores, which improved. No placebo group is described, so neither the effectiveness nor the safety of the dose can be inferred [1]B.

The study was published in Russian, and the dose is from its English abstract [1]B.

What points the other way or is uncertain

In a study of 32 people with multiple illnesses, pinealon and vesugen showed a pro-oxidant effect and a fall in blood CD34+ cells, which the authors interpreted as inhibition of blood formation [3]B.

All human studies are small Russian studies without a described placebo group [1, 2, 3, 4]B; two of them were done in Yekaterinburg [3, 4]B.

More on this

Read the research yourself: sources

  1. Nazimko VA, Morgul' EV, Petrova OA, et al. Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades. Adv Gerontol. 2012;25(1):57-62. (In Russian.) PMID 22708445
  2. Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional truck-drivers. Adv Gerontol. 2012;25(4):718-728. (In Russian.) PMID 23734521
  3. Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Adv Gerontol. 2015;28(1):62-67. (In Russian.) PMID 26390612
  4. Myakotnykh VS, Torgashov MN, Egorin KV, et al. Comparative analysis of different methods of geroprotective. Adv Gerontol. 2016;29(4):594-601. (In Russian.) PMID 28539017

Sources read on 15 Oct 2026 from the English abstracts of the publications; none has been retracted. All four articles were published in Russian.

Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.